Cost-effectiveness analyses of natalizumab (Tysabri) compared with other disease-modifying therapies for people with highly active relapsing-remitting multiple sclerosis in the UK. (Q42659627)
Jump to navigation
Jump to search
scientific article published on January 2008
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Cost-effectiveness analyses of natalizumab (Tysabri) compared with other disease-modifying therapies for people with highly active relapsing-remitting multiple sclerosis in the UK. |
scientific article published on January 2008 |
Statements
1 reference
Cost-effectiveness analyses of natalizumab (Tysabri) compared with other disease-modifying therapies for people with highly active relapsing-remitting multiple sclerosis in the UK. (English)
1 reference
Gavin Giovannoni
1 reference
Ray Gani
1 reference
David Bates
1 reference
Belinda Kemball
1 reference
Steve Hughes
1 reference
John Kerrigan
1 reference
1 January 2008
1 reference
1 reference
26
1 reference
7
1 reference
617-627
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
Identifiers
1 reference
1 reference